Courts & Litigation

Mainstream coverage this week focused on two high‑profile legal fights: the Musk v. Altman/OpenAI trial in federal court in Oakland, where Elon Musk’s team opened by seeking Sam Altman’s removal from OpenAI’s nonprofit board and massive disgorgement tied to OpenAI’s conversion to a for‑profit structure, and the Supreme Court hearing on whether federal pesticide law preempts state cancer‑warning suits over Roundup, where justices appeared sharply divided and questioned whether EPA labeling should foreclose state remedies. Reports noted jury selection and Judge Yvonne Gonzalez Rogers’ advisory‑juror role in the OpenAI case, the tens‑of‑billions disgorgement demand and disputed early Musk donations, and that the Roundup outcome could affect thousands of suits and national preemption doctrine without resolving glyphosate’s causal link to cancer.

Missing from much mainstream coverage were deeper legal and factual contexts that would help readers assess stakes and plausibility: clearer explanation of the practical and procedural effects of an advisory jury and disgorgement remedies, the precise range and sources of Musk’s early funding claims, the legal precedent and logistics for “rolling back” a corporate conversion, and more granular data on Roundup litigation (how many pending cases, relevant epidemiological meta‑analyses, and EPA risk findings). Opinion and analysis pieces picked up those wider implications — linking recent regulatory and legislative moves (including a contested farm bill and a revised judicial reference manual) to broader shifts in who sets scientific and liability standards — a perspective largely absent from straight news reports; contrary voices noted that the new manual aims to help judges with technical matters and that some industry experts defend glyphosate’s safety, while analysts warned the cases could nonetheless reshape corporate governance, evidentiary gatekeeping, and access to remedies.